Rapport Therapeutics’ Quiet Period Will Expire on July 17th (NASDAQ:RAPP)

Rapport Therapeutics’ (NASDAQ:RAPPGet Free Report) quiet period is set to end on Wednesday, July 17th. Rapport Therapeutics had issued 8,000,000 shares in its public offering on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. During Rapport Therapeutics’ quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analyst Ratings Changes

RAPP has been the topic of several research analyst reports. TD Cowen began coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 2nd. They issued a “buy” rating on the stock. Stifel Nicolaus initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price target on the stock. Finally, Jefferies Financial Group initiated coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price objective for the company.

View Our Latest Report on Rapport Therapeutics

Rapport Therapeutics Stock Performance

Shares of RAPP opened at $25.89 on Friday. Rapport Therapeutics has a 52-week low of $18.00 and a 52-week high of $27.14.

Insider Buying and Selling

In other Rapport Therapeutics news, Director James Healy acquired 44,032 shares of the business’s stock in a transaction on Monday, July 1st. The stock was bought at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the acquisition, the director now owns 40,851 shares in the company, valued at $1,001,666.52. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

About Rapport Therapeutics

(Get Free Report)

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.

See Also

Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.